<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426737</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237ACH02T</org_study_id>
    <nct_id>NCT01426737</nct_id>
  </id_info>
  <brief_title>The Swiss Glucose Variability Study</brief_title>
  <official_title>The Swiss Glucose Variability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore long term glucose variability of a combination&#xD;
      therapy of metformin and vildagliptin compared to a metformin - gliclazide combination.&#xD;
&#xD;
      Multicenter, randomized, open, parallel group, Phase IV study, of 18 months duration.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).</measure>
    <time_frame>48h</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or female patients aged =30 -= 75 years.&#xD;
&#xD;
          2. History of type 2 diabetes for at least 6 months.&#xD;
&#xD;
          3. Patients inadequately controlled (i.e. not reaching target) with maximum tolerated&#xD;
             doses of metformin with HbA1c of 6.5-9.0%.&#xD;
&#xD;
          4. Patients inadequately controlled (i.e. not reaching target) with maximum tolerated&#xD;
             doses of metformin with a body mass index (BMI) of 25-40 kg/m2.&#xD;
&#xD;
          5. Patients that are currently treated with metformin, gliclazide or both but not with&#xD;
             other glucose lowering agents.&#xD;
&#xD;
          6. Outpatient.&#xD;
&#xD;
          7. If female of childbearing potential: Will to practice reliable birth control measures&#xD;
             [e.g., surgical sterilization, hormonal contraception, double-barrier methods (any&#xD;
             double combination of IUD, male or female condom with spermicidal gel, diaphragm,&#xD;
             sponge, cervical cap)] during study treatment and for at least 28 days after&#xD;
             completion of study medication; not lactating or pregnant; and has a documented&#xD;
             negative pregnancy test result at baseline.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Type 1 diabetes as defined by the American Diabetes Association (ADA).&#xD;
&#xD;
          2. Type 2 diabetes currently (last 3 months) treated with insulin or glitazones.&#xD;
&#xD;
          3. Acute or chronic diseases causing tissue hypoxia such as:&#xD;
&#xD;
               -  cardiac or respiratory insufficiency&#xD;
&#xD;
               -  myocardial infarct within the last 6 months&#xD;
&#xD;
          4. Active liver disease with alanine aminotransferase (ALAT) and / or aspartate&#xD;
             aminotransferase (ASAT) &gt; 3 x upper limit of normal.&#xD;
&#xD;
          5. Relevant kidney disease such as :&#xD;
&#xD;
               -  serum creatinine =133 µmol/l in males and &gt; 124 µmol/l in females&#xD;
&#xD;
               -  proteinuria &gt; 300 mg/l&#xD;
&#xD;
               -  status post kidney transplantation&#xD;
&#xD;
               -  severe infection&#xD;
&#xD;
               -  intravascular administration of contrast medium containing iod within the last 7&#xD;
                  days&#xD;
&#xD;
          6. Severe neuropathy (vibration perception at the base of the big toes &lt;2/8).&#xD;
&#xD;
          7. Active proliferative diabetic retinopathy.&#xD;
&#xD;
          8. Any clinically relevant major organ system disease including mental illnesses&#xD;
&#xD;
          9. History of malignancy&#xD;
&#xD;
         10. Pancreatitis&#xD;
&#xD;
         11. Porphyria&#xD;
&#xD;
         12. Severe disturbances of the adrenal gland&#xD;
&#xD;
         13. Severe disturbances of the thyroid gland&#xD;
&#xD;
         14. Allergy to vildagliptin or one of the excipients&#xD;
&#xD;
         15. Allergy to metformin or one of the excipients&#xD;
&#xD;
         16. Allergy to gliclazide, sulfonylurea or sulfonamides or one of the excipients.&#xD;
&#xD;
         17. Drug or alcohol abuse.&#xD;
&#xD;
         18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive pregnancy test (serum or urine).&#xD;
&#xD;
         19. Any other condition that could interfere with the participation in the study according&#xD;
             to the study protocol or with the ability to cooperate and comply with the study&#xD;
             procedures.&#xD;
&#xD;
         20. Treatment with any investigational drug, within 30 days or 5 half-lives before&#xD;
             screening, whichever is longer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <phone>+41 (0)44 255 11 11</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Universitiy Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

